Aspirin desensitization in patients with aspirin-induced and aspirin-tolerant asthma: A double-blind study

• Published in: Journal of allergy and clinical immunology Vol. 134; no. 4; pp. 883 - 890
• Main Authors: Świerczyńska-Krępa, Monika, MD, PhD, Sanak, Marek, MD, PhD, Bochenek, Grażyna, MD, PhD, Stręk, Paweł, MD, PhD, Ćmiel, Adam, PhD, Gielicz, Anna, PhD, Plutecka, Hanna, PhD, Szczeklik, Andrzej, MD, PhD, Niżankowska-Mogilnicka, Ewa, MD, PhD
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier Inc 01.10.2014; Elsevier; Elsevier Limited
• Subjects: Administration, Oral; Adult; Aged; Allergens - immunology; Allergy and Immunology; Aspirin; Aspirin - administration & dosage; Aspirin - immunology; Aspirin-induced asthma; aspirin-tolerant asthma; Asthma; Asthma - diagnosis; Asthma - immunology; Asthma - therapy; Asthma, Aspirin-Induced - diagnosis; Asthma, Aspirin-Induced - immunology; Asthma, Aspirin-Induced - therapy; Biological and medical sciences; Chronic Disease; Chronic obstructive pulmonary disease, asthma; Desensitization, Immunologic - methods; Dinoprost - blood; Double-Blind Method; Drug dosages; Drug therapy; Eosinophils - immunology; Female; Follow-Up Studies; Fundamental and applied biological sciences. Psychology; Fundamental immunology; Humans; Immunopathology; Leukotriene E4 - urine; Male; Medical sciences; Middle Aged; Nasal Polyps - diagnosis; Nasal Polyps - immunology; Nasal Polyps - therapy; oral aspirin desensitization; Pilot Projects; Pneumology; Prostaglandin D2 - blood; Rhinitis - diagnosis; Rhinitis - immunology; Rhinitis - therapy; Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis; Sinusitis - diagnosis; Sinusitis - immunology; Sinusitis - therapy; Spirometry; Treatment Outcome; uLTE 4; 9α,11β-PGF 2; Cysteinyl leukotriene; NSAID; LTE 4; Urinary LTE 4; L-ASA; Acetylsalicylic acid; ASA; Aspirin-induced asthma; Computed tomography; Aspirin desensitization; AIA; 9α,11β-Prostaglandin F 2; Leukotriene E 4; Lysine-aspirin; AD; Prostaglandin; Inhaled corticosteroid; SNOT20; ATA; cysLT; ACQ; Asthma Control Questionnaire; PEF; CT; Peak nasal inspiratory flow; oral aspirin desensitization; Nonsteroidal anti-inflammatory drug; PG; aspirin-tolerant asthma; ICS; Peak expiratory flow; Sino-Nasal Outcome Test; PNIF; 9α,11β-PGF2; LTE4; uLTE4; Human; Lung disease; Prostaglandin-endoperoxide synthase; Immunopathology; Desensitization; Enzyme; Respiratory disease; Oral administration; Enzyme inhibitor; Antiplatelet agent; Asthma; Immunology; Double blind study; Bronchus disease; Obstructive pulmonary disease; Oxidoreductases; Salicylates

Background Numerous open trials have demonstrated the beneficial clinical effects of aspirin desensitization (AD) in patients with aspirin-induced asthma (AIA). These beneficial effects might be attributable to aspirin's potent anti-inflammatory properties, but that supposition requires further...